S erotonin (5-hydroxytryptamine, 5-HT), a biogenic monoamine widely distributed in the animal and plant kingdoms, exerts complex effects in the periphery and in the central nervous system. Although the effects attributable to 5-HT have been known since the 19th century l2, its physiological and pathophysiological importance, including its role in cardiovascular regulation, remain unclear3.*. However, in many respects, 5-HT would seem an ideal neurohumoral transmitter candidate for the cardiovascular system. Secreted from enterochromaffin cells into the blood, 5-HT is stored by platelets. During aggregation, usually at a site of vascular injury, platelets release 5-HT, thus providing a unique mechanism for local delivery. Moreover, circulating 5-HT can be taken up by sympathetic neurons and vascular endothelial cells and could, subsequently, be coreleased5,". ) and operational (drug-related) criteria, 5-HT receptors are now categorized into five main type&-l3 (see Table 1 ): l 5-HT,. which corresponds to some 'D' receptors and 5-HT, binding sites and can be subdivided into functional subtypes , , , , , , , ) ; Table 1 In addition, this current classification includes certain recombinant (5-ht,,, 5-ht,,, 5-ht,,, 5-ht,, and 5-h@ and ' orphan' receptors awaiting definitive characterization. It is noteworthy that the arrival of sumatriptanr* led to the subdivision of 5-carboxamidotryptamine-sensitive 5-HT,-like receptors into 5-HT,, (sumatriptan-sensitive) and 5-HT,, (sumatriptan-insensitive) receptord. Utilizing their differential coupling to adenylate cyclase and employing new cloning techniques, it was shown that j-HT,, (vasoconstrictor) and j-HT,, (vasodilator) receptors are different and appear to correspond to j-HTrB1rD (Refs 15,16) and j-HT, (Ref. 17) receptors, respectively. Cardiovascular responses mediated by 5-HT receptors The effects of 5-HT in the cardiovascular system are complex because they consist of bradycardia or tachycardia, hypotension or hypertension, and vasodilatation or vasoconstriction. Considering the above classification criteria, the cardiovascular effects of j-HT are mediated by five main sets of receptors: j-HT, , , &, , , (Refs 3, 4, (15) (16) (17) (18) (19) (20) .
Intravenous injection of j-HT usually lowers heart rate via the von Bezold-Jarisch reflex, mediated by 5-HT, receptors on sensory vagal nerves in the heart, When this reflex is suppressed (e.g. by vagotomy or spinal section), 5-HT increases the heart rate in different species by a variety of direct and indirect mechanisms*,r8.21, including: On the other hand, the blood pressure response to 5-HT is usually triphasic and consists of an initial short-lasting hypotension caused by bradycardia (von Bezold-Jarisch reflex), a middle pressor phase and a late, longer-lasting, hypotension.
The pressor response is a result of vasoconstriction mediated mainly by 5-HT, receptors3. Finally, the late depressor response may involve four different mechanisms: In addition, 5-HT-induced constriction in a number of blood vessels, particularly the large arteries and arteriovenous anastomoses of the cranial extracerebral region (e.g. human middle meningeal arteryzx-Jo and pig and dog external carotid arterial bed'?), is mediated by j-HT,,,,, (most likely 5-HT,,$ receptors. Although mRNA for the 5-ht,, receptor has been located in the human middle meningeal artery29, activation of this receptor does not appear to contribute to 5-HT-or sumatriptan-induced contractions of this vesseljo.
5-HT-related
drugs in cardiovascular pathologies The cardiovascular pharmacology of 5-HT suggests that compounds acting on 5-HT receptors can be employed for therapeutic use in the treatment of migraine, hypertension and some peripheral vascular diseasesA,+z3i-33. In particular, the recent recognition of the 5-HT, receptor as a functional receptor will undoubtedly disclose more therapeutic possibilities. Indeed, a large number of pharmaceutical companies 296 are currently interested in serotonergic drugs+, and the patenting activity indicates that these companies expect to convert new chemical entities into marketable products for therapeutic use. The established, as well as some potential, therapeutic uses of 5-HT receptor agonists and antagonists are listed in Table 2 .
Migraine
Many studies have conclusively shown that sumatriptan, an agonist at the 5-HT,,;,, receptors mediating constriction of cranial large arteries and arteriovenous anastomosesi*,rj,34, is effective in aborting migraine attackG3j. The success of this drug has prompted a large number of pharmaceutical companies to develop novel 5-HT,,,,, receptor agonists* ( Table 2 ). In particular, efforts are being directed towards making more lipid-soluble and selective compounds to improve oral bioavailability and to avoid coronary artery vasoconstriction. Although the new 5-HT,,,,, receptor agonists such as rizatriptan, zolmitriptan and naratriptan ( Figure 1 and Table 3 ) appear to have a better oral bioavailability33, they do not seem to differ with respect to their coronary side effect potentiap6.
We believe that vasoconstriction in the extracerebral (intra-and extracranial) blood vessels, which appear to be dilated during migraine, is mainly responsible for the therapeutic effect of sumatriptan33. However, other mechanisms, such as inhibition of central trigeminal neuron@ or neurogenie plasma extravasation38, have also been suggested. Phebus and coworkers39 have argued that the inhibition of plasma extravasation as well as the therapeutic activity of sumatriptan is mediated via the 5-ht,, receptor. Therefore, they surmise that LY334370 (Figure l) , which lacks vasoconstrictor activity (on rabbit saphenous vein) but has a selective agonist action at the 5-ht,, receptor (Table 3) and blocks plasma extravasation following trigeminal nerve stimulation, may potentially be a better antimigraine agent than sumatriptan3". However, in our opinion, the following facts do not support the above hypothesis: l Some compounds, such as neurokinin NK, and endothelin ET,,a receptor antagonists and CP122288 (Figure 1 and Table 3 ), all of which potently inhibit plasma extravasation4w2, failed to show clinical efficacy in migraine4*6. The 5-HT,,,,n receptor agonists rizatriptan and alniditan (Figure l) , which are effective in migraineso, have little affinity for the 5-ht,, receptor (Table 3) 5l. Whether an agonist action at the 5-ht,, receptor can also confer antimigraine action remains to be seen, and the results of clinical trials with LY334370 are awaited with interest.
Some antimigraine drugs (methysergide, pizotifen, ergotamine, dihydroergotamine) are potent antagonists at 5-HT, receptors, but many other 5-HT,, antagonists (ketanserin, cyproheptadine, mianserin, methiothepin) are not of much use in migraine therapyjz. More recently, it has been proposed that 5-HT,, 2c receptors may be involved in the initiation of migraine attacksz',j3.j4. Thus, selective antagonism of these receptors, in particular the 5-HT,, receptor, which may mediate nitric oxide release from vascular endotheliumi2.27, should be effective in migraine preventionj3,j*. However, as already discussed elsewherej*. several 5-HTzB1,c receptor antagonists, including mianserin and cyproheptadine, are not very effective antimigraine agents. It seems, therefore, that additional properties, such as vasoconstriction in the extracerebral cephalic circulation in the case of methysergide, ergotamine and dihydroergotamine (partly via Systemic, pulmonary and portal hypertension Both urapidil (5-HT,, receptor agonist) and ketanserin (5-HT,, receptor antagonist) are approved for the treatment of systemic hypertension Indeed, it is claimed that these drugs decrease blood pressure by stimulating 5-HT,, receptors located centrally in the nucleus tractus solitarii (urapidil) or by blocking 5-HT,, receptors mediating peripheral vasoconstriction (ketanserin). However, as discussed in detail elsewherej, it seems that such effects are not involved to a significant degree in the clinical effects of these drugs; both urapidil and ketanserin have a potent a,-adrenoceptor antagonist activity, which can adequately explain their antihypertensive effect,
In view of the arteriolar vasodilatation mediated by the 5-HT, receptorj9. it may be worthwhile exploring selective agonists at this receptor as antihypertensive agents. In this regard, however, one should be aware of the competition with excellent drugs already available.
In the complex setting of cardiac surgery and cardiopulmonary bypass, several potent mediators are released, which, in turn, may produce systemic and/or pulmonary hypertension. One of the mediators may be 5-HT, released from aggregating platelets, causing vasoconstriction by activating 5-HT, receptors, particularly in patients with an impaired endothelial function (e.g. atherosclerosis@). Ketanserin has proved effective in the treatment of postoperative pulmonary hypertension61. It is far from clear, 5-HTnm receptors) and antidepressant action in the case of pizotifen, may be necessary for therapeutic actionjj. Similarly, because no clearcut positive antimigraine effect has been found for any of the 5-HT, receptor antagonists@s', this receptor does not appear to play a major role in migraine.
Lastly, it may be pointed out that the constriction of porcine carotid arteriovenous anastomoses elicited by ergotamine, dihydroergotamine or 5-HT (the latter in the presence of ketanserin) is not very susceptible to blockade by GR127935. This suggests the involvement of a receptor other than the 5-HTz, and 5-HTIB1iD receptor@. It will be interesting to characterize this receptor further and explore whether it can be a target for developing novel antimigraine drugs. however, whether 5-HT, receptor blockade is responsible for the effectiveness of ketanserin, since no selective 5-HT, receptor antagonists have been shown to be effective.
On the other hand, the ability of 5-HT, receptor agonists to increase atria1 contractility suggested that these drugs may have application in the therapy of heart failure. Any such hopes were dashed, however, when it was shown that 5-HT, receptors are not present on human ventricles65.66.
Perhaps less questionable is the role of 5-HTz receptors in some cases of portal hypertension, where higher levels of free plasma 5-HT are found in the portal venous circulation3*. This assumption is based on the fact that both ketanserin (which combines 5-HT, with a,-adrenoceptor blockade) and ritanserin (at doses without a,-adrenoceptor blockade) lower portal venous pressureb2.
Peripheral vascular diseases
Pre-eclampsia and eclampsia Ketanserin has been shown to be effective in the treatment of pre-eclampsia and eclampsia, pathologies that seem to involve local release of 5-HT from aggregating platelets in the placental circulation32.63. Although this finding does not establish the involvement of 5-HT, receptors, this hypothesis could be substantiated by establishing the effectiveness of selective 5-HT, receptor antagonists.
5-HT has been implicated in the pathophysiology of peripheral vascular diseases, but the evidence is not compelling67. Although some clinical trials show a moderate efficacy of ketanserin"', this drug is not registered for this indication in The Netherlands. However, it is interesting to note that one of the prominent cardiovascular effects of 5-HT is its ability to produce vasodilatation via stimulation of 5-HT, receptors17,20. Therefore, selective agonists at vascular 5-HT, receptors may be expected to enhance capillary blood flow and be useful in the treatment of peripheral vascular diseases, including trophic skin ulcers. This approach might also have potential applications, as yet unexplored, in the medical treatment of skin grafts and baldness.
Cerebral ischaemia
Carcinoid syndrome The carcinoid syndrome is a pathology characterized predominantly by gastrointestinal alterations (e.g. diarrhoea) and facial flushing, provoked by a tumour secreting a gross excess of several mediators, including . Ketanserin has been claimed to be effective in diminishing the frequency and severity of some manifestations of this syndrome, including diarrhoea and flushings*. Nevertheless, considering that 5-HT-induced arteriolar vasodilatation is mediated mainly by 5-HT, receptors5", the clinical effectiveness of ketanserin in relieving facial flushing by blockade of Buspirone and ipsapirone, established anxiolytic agents with an action at central 5-HT,, receptors+, decrease infarct size in animal models of focal"8 and global"" cerebral ischaemia. Notwithstanding, the involvement of 5-HT,, receptors is questionable because these drugs are nonselective agents and, most significantly, Shydroxy-2-(di-n-propylamino)-tetralin (S-OH-DPAT). which is also a potent 5-HT,, receptor agonist12, was ineffective in these experimental models6~70.
Closing remarks During the last decade, research in the field of 5-HT has been boosted by the availability of potent and selective DDT Vol. 2, No. 7 July 1997 drugs. These drugs and the increasing understanding of transduction mechanisms, as well as the structure of the receptor protein, have enabled a more meaningful characterization and nomenclature of 5-HT receptors, Thus, five main classes with several subtypes (5-HT,, 5-HT,, 5-HT,, 5-HT, and 5-HT,) as well as some not yet adequately characterized recombinant (e.g. 5-ht,,, 5-ht,,, j-ht,,, 5-ht,,, 5-ht,) and 'orphan' 5-HT receptors have been recognized, Indeed, the molecular cloning and expression of a growing number of 5-HT receptors in host cells now offers the possibility to screen new molecules easily. This will help identify selective ligands, which could, in turn, provide access to better drugs for a more efficient treatment of human ailments.
